Sıçanlarda Hepatik İskemi Reperfüzyon Hasarında Farklı Dozlarda Amantadin'in Akciğer Dokusu Üzerine Etkisi

Year 2022, , 520 - 525, 20.10.2022

Fatih Şahin , Mustafa Orhan , Ayça Taş Tuna , Onur Palabıyık , Nevcihan Şahutoğlu Bal , Sezen Irmak Gözükara , Özcan Budak , Hüseyin Çakıroğlu

https://doi.org/10.18521/ktd.1161896

Abstract

Amaç: N-Metil D-Aspartat (NMDA) reseptör blokerlerinin çeşitli dokularda iskemi/reperfüzyon (I/R) hasarına karşı koruyucu etkileri olduğu gösterilmiştir. Bu çalışmanın amacı, hepatik I/R hasarında 90 ve 135 mg/kg dozlarındaki amantadinin akciğer üzerindeki etkilerini araştırmaktır.
Gereç ve Yöntem: Sıçanlar her rastgele altı gruba ayrıldı: Grup Sham, Grup I/R, Grup Amantadin-90, Grup Amantadin-135, Grup I/R-90 ve Grup I/R-135. I/R'de sol portal triaddaki yapılara 45 dakika süre ile atravmatik vasküler klemp uygulandı ve iskemi sonrası 2 saat reperfüzyon uygulandı. Akciğer dokusunda malondialdehit (MDA), süperoksit dismutaz (SOD) ve katalaz (CAT) enzim düzeyleri ölçüldü ve dokular histopatolojik olarak incelendi.
Bulgular: MDA, SOD, CAT düzeyleri açısından gruplar arasında anlamlı fark bulundu (sırasıyla; p < 0,001, p=0,008, p < 0,001). Akciğer dokusu nötrofil/lenfosit infiltrasyon skorları ve alveolar duvar kalınlaşma skorları açısından gruplar arasında anlamlı fark bulundu (sırasıyla p=0,009, p=0,002).
Sonuç: Bu çalışmanın biyokimyasal ve histopatolojik sonuçları, hem 90 hem de 135 mg/kg dozdaki amantadinin, diğer NMDA antagonist ajanları gibi, karaciğer I/R hasarının neden olduğu hasara karşı akciğer dokuları üzerinde koruyucu bir etkiye sahip olabileceğini göstermiştir. Çalışılan her iki dozun uygulanmasından sonra önemli gelişmeler gözlemlememize rağmen, uzak organ akciğer hasarına karşı korumadaki başarıları açısından bu iki doz arasında anlamlı bir fark yoktu. Amantadin, tedavide terapötik bir ajan olarak umut verici görünmektedir.

Keywords

Amantadin, İskemi Reperfüzyon Hasarı, Akciğer Hasarı, Uzak Organ Hasarı

Supporting Institution

yok

Project Number

yok

The Effect of Different Doses of Amantadine on Lung Tissue In Hepatıc Ischemia Reperfusion Injury in Rats

Abstract

Objective: N-Methyl D-Aspartate (NMDA) receptor blockers have been shown to have protective effects against ischemia/reperfusion (I/R) injury in various tissues. The aim of this study was to investigate the effects of 90 ve 135 mg/kg doses of amantadine on lung in hepatic I/R injury.
Method: The rats were randomly divided into six groups: Group Sham, Group I/R, Group Amantadine-90, Group Amantadine-135, Group I/R-90 and Group I/R-135. In I/R, an atraumatic vascular clamp was applied to the structures in the left portal triad for 45 minutes and reperfusion period was 2 hours after ischemia. Malondialdehyde (MDA), superoxide dismutase (SOD) and catalase (CAT) enzyme levels were performed the lung tissue and tissues were examined histopathologically.
Result: A significant difference was found between the groups in terms of MDA, SOD, CAT levels (respectively; p < 0.001, p=0.008, p < 0.001). A significant difference was found between the groups in terms of lung tissue neutrophil/lymphocyte infiltration scores and alveolar wall thickening scores (respectively p=0.009, p=0.002).
Conclusion: The biochemical and histopathological results of the present study suggested that amantadine, like other NMDA antagonist agents, may have a protective effect on lung tissues against the damage caused by hepatic I/R injury. Although we observed significant improvements after the administration of both doses studied, there was no significant difference between these two doses in terms of their success in protecting against distant organ lung injury. Amantadine appears promising as a therapeutic agent in treatment.

Keywords

Amantadine, Ischemia reperfusion injury, Lung injury, Remote organ damage

Project Number

yok

References

• 1. Konishi T, Lentsch AB. Hepatic Ischemia/Reperfusion: Mechanisms of Tissue Injury, Repair and Regeneration. Gene Expr 2017; 17(4): 277-87.
• 2. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Ischemia/reperfusion. Compr. Physiol 2016; 7: 113
• 3. Peralta C, Jiménez-Castro MB, Gracia-Sancho J. Hepatic ischemia and reperfusion injury: effects on the liver sinusoidal milieu. J. Hepatol 2013; 59: 1094-106.
• 4. Miranda LC, Capellini V, Reis G, Celotto A , Carlotti Jr C, Evora PR. Effects of partial liver ischemia followed by global liver reperfusion on the remote tissue expression of nitric oxide synthase:lungs and kidneys. Transplant Proc 2010 Jun; 42(5): 1557-62.
• 5. Tufek A, Tokgoz O, Aliosmanoglu I, et al. The protective effects of dexmedetomidine on the liver and remote organs against hepatic ischemia reperfusion injury in rats. Int J Surg 2013; 11(1): 96-100.
• 6. Sun H, Zou S, Candiotti KA, et al. Octreotide attenuates acute kidney injury after hepatic ischemia and reperfusion by enhancing autophagy. Sci Rep 2017; 7: 42701.
• 7. Zhou L, Zhao D, An H, Zhang H, Jiang C, Yang B. Melatonin prevents lung injury induced by hepatic ischemia–reperfusion through anti-inflammatory and anti-apoptosis effects. Int Immunopharmacol 2015 Dec; 29(2): 462-7.
• 8. Nakamura K, Yazawa T, Kawaguchi Y, et al. High tidal volume ventilation induces lung injury after hepatic ischemia-reperfusion. Am J Physiol Lung Cell Mol Physiol 2007; 292: 625-31.
• 9. Okigbo AA, Helkowski MS, Royes BJ, et al. Dose-dependent neurorestorative effects of amantadine after cortical impact injury. Neurosci Lett 2019: Feb 16; 694:69-73.
• 10. Yamanaka K, Houben P, Bruns H, Schultze D, Hatano E, Schemmer P. A Systematic review of pharmacological treatment options used to reduce ischemia reperfusion injury in rat liver transplantation. PLoS One 2015; 10(4): e0122214.
• 11. Himmelseher S, Durieux, M.E. Revising a dogma: ketamine for patients with neurological injury. Anesth Analg 2005: 101; 524-53.
• 12. Lee HT, Ota-Setlik A, Fu Y, Nasr SH, Emala CW. Differential protective effects of volatile anesthetics against renal ischemia–reperfusion injury in vivo. Anesthesiology 2004: 101; 1313-24.
• 13. Kato R, Foëx P. Myocardial protection by anesthetic agents against ischemia–reperfusion injury: an update for anesthesiologists. Can J Anaesth 2002: 49(8), 777-91.
• 14. Orhan M, Tuna Taş A, Ünal Y, Arslan M, Yazar H, Sezen Cem Ş, et al. The effects of amantadine on lung tissue in lower limb ischemia/reperfusion injury model in rats. Turk Gogus Kalp Dama 2021;29:077-083
• 15. Sehirli O, Ozel Y, Dulundu E, Topaloglu U, Ercan F, Sener G. Grape seed extract treatment reduces hepatic ischemia-reperfusion injury in rats. Phytother Res 2008 Jan; 22(1): 43-8.
• 16. Cámara-Lemarroy CR, Guzmán-de la Garza FJ, Alarcón-Galván G, Cordero-Pérez P, Fernández-Garza NE: The effects of NMDA receptor antagonists over intestinal ischemia/reperfusion injury in rats. Eur J Pharmacol 2009; 621: 78–85.
• 17. Ke T, Li R, Chen W. Inhibition of the NMDA receptor protects the rat sciatic nerve against ischemia/reperfusion injury. Experimental and Therapeutic Medicine 2016; 11: 1563-72.
• 18. Takhtfooladi MA, Jahanshahi A, Sotoudeh A, Daneshi MH, Khansari M, Takhtfooladi HA. The antioxidant role of N-acetylcysteine on the testicular remote injury after skeletal muscle ischemia and reperfusion in rats. Pol J Pathol 2013; 64(3): 204-9.
• 19. Sahin T, Begeç Z, Toprak Hİ, et al. The effects of dexmedetomidine on liver ischemia-reperfusion injury in rats. J Surg Res 2013 Jul; 183(1): 385-90
• 20. Kireev R, Bitoun S, Cuesta S, et al. Melatonin treatment protects liver of Zucker rats after ischemia/reperfusion by diminishing oxidative stress and apoptosis. Eur J Pharmacol 2013; 701: 185-93.
• 21. Mates JM, Perez-Gomez C, Castro IN. Antioxidant enzymes and human disease. Clin Biochem 1999; 32(8): 595-603.
• 22. Kucuk A, Yaylak F, Cavunt- Bayraktar A, et al. The protective effects of dexmedetomidine on hepatic ischemia reperfusion injury. Bratisl Lek Listy 2014; 115(11); 680-4.
• 23. Kapan S, KiriS I, Kılbas A, Altuntas I, Karahan N, Okutan H. The effect of erythropoietin on lung injury in rat aortic ischemia-reperfusion. Turkish J Thorac Cardiovasc Surg 2009; 17(2): 110-6.
• 24. Gu, J, Korteweg, C. Pathology and pathogenesis of severe acute respiratory syndrome. Am J Pathol 2007; 170(4): 1136-47.
• 25. Aduen JF, Stapelfeldt WH, Johnson MM, et al. Clinical relevance of time of onset, duration, and type of pulmonary edema after liver transplantation. Liver Transplant 2003 Jul; 9(7); 764-71.
• 26. El-Sayed LA, Osama E, Mehesen MN, et al. Contribution of angiotensin II in hepatic ischemia /reperfusion induced lung injury: Acute versus chronic usage of captopril. Pulmonary Pharmacology & Therapeutics 2020; 60: 101888.
• 27. Canedo LF, Lima GV, Machado MCC. Pulmonary effects after partial liver ischemia and reperfusion – experimental model. Revista Do Colegio Brasileiro De Cirurgioes. 2012; 39(3): 216-21.